Top Markets
#1 NKN NKN +160.00%
#2 Bluwhale Bluwhale +34.89%
#3 Codatta Codatta +30.46%
#4 SAFEcoin SAFEcoin +28.54%
#5 Saakuru Saakuru +24.27%
#6 StakeStone StakeStone +19.16%
#7 Particle Network Particle Network +18.79%
#8 Yooldo Games Yooldo Games +15.38%
#9 Arcblock Arcblock +14.06%
#10 Ski Mask Dog Ski Mask Dog +13.94%
Coin of the day
NKN NKN
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Classifica tra le azioni #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Prezzo delle azioni
$0.15
Capitalizzazione di mercato
$4.96M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
CA
Scambia Intellipharmaceutics International Inc. (IPCIF)

Categoria

Healthcare
Storico del prezzo dell'azione per Intellipharmaceutics International Inc. (IPCIF)
Prezzo di chiusura più alto: $0.15 il 2024-11-01

Prezzo di chiusura più basso: $257.83 il 2009-10-01
Storico del prezzo dell'azione di Intellipharmaceutics International Inc. dal 2009 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2024 115.80%
2023 -6.42%
2022 -39.73%
2021 -13.08%
2020 -62.82%
2019 52.02%
2018 -96.81%
2017 -71.95%
2016 34.10%
2015 -16.95%
2014 -27.81%
2013 48.05%
2012 -19.79%
2011 11.50%
2010 56.06%
2009 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $36.40 -49.25%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $453.74 -9.30%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $756.73 18.21%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $298.08 65.31%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $692.83 18.70%
NL